Tirzepatide versus semaglutide In the direct head-to-head comparison, the 1-year risk of the primary endpoint including all-cause mortality was 1.3% (95% CI 1.2% to 1.5%) for tirzepatide and 1.3% (95% CI 1.2% to 1.5%) for semaglutide, resulting in a risk difference of 0.0% (95% CI 0.2% to 0.2%) and an HR of 1.06 (95% CI 0.95 to 1.18) (Fig
Its a slow burn patience and lifestyle changes alongside it make a real difference.
A direct effect of tirzepatide at the GIPR in adipose tissue surrounding and within the kidney, such as perirenal fat and intrarenal fat, may favorably affect inflammation known to contribute to kidney dysfunction
The full therapeutic dose may not be reached until 16 to 20 weeks after initiation, which delays maximal efficacy but improves tolerability and treatment adherence
Its just Ozempic does fit, even though its wrong
Check them out on our YouTube channel